|Bid||54.50 x 200|
|Ask||54.76 x 100|
|Day's Range||62.01 - 64.49|
|52 Week Range||28.08 - 68.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.00|
CEO of pharmaceutical company Mylan, Heather Bresch, sits down the Yahoo Finance's Andy Serwer and Jen Rogers to discuss what the future holds for the drug company.
Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $206 million.
NEW YORK, NY / ACCESSWIRE / February 16, 2018 / U.S. markets continued to rally for the fifth consecutive day on Thursday, after being hit with a sharp correction last week. The Dow Jones Industrial Average ...
NEW YORK, Feb. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Morgan ...
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Sarepta shares closed in the red on Friday after the company's Essence study was halted in the U.K. Shares of Sage Therapeutics also closed down after announcing ...
Sarepta Therapeutics Inc (NASDAQ:SRPT) stock was hit hard today after reports claim one of its studies was put on hold. According to these recent reports, Sarepta Therapeutics Inc had to put its Essence study on hold in the U.K. The reason given is that there was “one serious adverse event” that may be connected to the drugs still in testing. The hold on the project reportedly started last week and Sarepta Therapeutics Inc has been unable to resume testing due to certain rules in the U.K. However, the trail is still progressing forward in other countries.
Sarepta Therapeutics confirmed Friday that U.K. regulators have temporarily halted a late-stage trial of two drugs for the muscle-wasting diseases Duchenne muscular dystrophy after one patient experienced a serious medical issue. In a statement, Cambridge-based Sarepta (SRPT) said the patient’s medical issue “could possibly be related” to the blinded study, in which patients were given one of two drugs, called golodirsen and casimersen, or else a placebo. An independent committee reviewed the safety data and said the trial could resume, but the U.K.’s Medicine and Healthcare products Regulatory Agency, or MHRA, nonetheless ordered Sarepta to halt the study, the company said.
Sarepta Therapeutics Inc. shares dropped 6% in extremely heavy morning trade Friday after a report by new analysis service EP Vantage said that the biotech had halted treatment at United Kingdom sites ...
CAMBRIDGE, Mass., Feb. 08, 2018-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular ...
A biotech investor shares a few reflections on adaptive ski coaching: By bringing together his passion for the mountains with his profession as an investor in biomedical therapies, adaptive coaching completes the circle by focusing on the most important of life’s elements — the human element.
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / The markets recent selloff continued Monday as a result of rising interest rates. Both the Dow Jones and the S&P 500 fell sharply to close in negative territory ...
CAMBRIDGE, Mass., Feb. 05, 2018-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular ...
Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. ETFs that hold SRPT had net inflows of $172 million over the last one-month.
CAMBRIDGE, Mass., Jan. 31, 2018-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular ...
Shares of gene therapy companies fell sharply Tuesday, after a report by a prominent scientist revealed the safety concerns that led him to resign recently from Solid Biosciences Inc.’s scientific advisory ...
Shares of AveXis and Solid Biosciences have been depressed in morning trading after the publication of an article in the medical journal Human Gene Therapy about severe toxicity in two animal species from administration of a gene therapy similar to one used by AveXis for spinal muscular atrophy, or SMA. The article was co-authored by James Wilson, director of gene therapy in the Department of Medicine at the University of Pennsylvania, who stepped down from Solid’s scientific advisory board shortly before the company’s recent initial public offering. Shares of AveXis (AVXS), a leader in gene therapy, are off $2.53, or 2%, to around $120 after touching a low of $110 earlier in the session.
Solid Biosciences (SLDB) pulled off its IPO late Thursday but had to price the deal below its most recent pricing range after the company made a surprise disclosure early Thursday about a partial clinical hold involving its critical clinical trial for a gene therapy treatment for Duchenne muscular dystrophy (DMD). In its amended IPO prospectus Thursday, Solid stated the Food and Drug Administration won’t allow the company to treat patients in its initial phase 1/2 clinical trial with a high dose of the gene therapy until it resolves certain manufacturing issues. The company, in the amended filing, downplayed the development, saying that it plans to address the manufacturing issues raised by the FDA and that it doesn’t expect the “overall timing for clinical development of SGT-001 will be affected by the partial clinical hold.” SGT-001 is the DMD gene therapy.
The Solid Biosciences initial public offering scheduled for Thursday suffered a potential setback when the company disclosed today in a regulatory filing that there is a partial clinical hold involving its critical early-stage clinical trial of a gene-therapy treatment for Duchenne muscular dystrophy, a fatal muscle-wasting genetic disease affecting between 10,000 and 15,000 boys and young men in the U.S. The surprising disclosure was outlined in a November 2017 letter from the Food and Drug Administration. The agency won’t allow the company to treat patients in the trial with a high dose of the gene therapy until it resolves certain manufacturing issues. Solid Biosciences can treat patients at a lower dose.
For Solid Biosciences CEO Ilan Ganot, the company’s initial public offering, expected on Thursday, will mark more than just a professional triumph. Solid is working to develop a gene therapy and possible cure for Duchenne muscular dystrophy, or DMD, a fatal muscle-wasting disease affecting boys, including Ganot’s son Eytani. DMD, a genetic disease, usually leaves patients in a wheelchair by their early teens, and leads to death from respiratory or heart failure, often by the early 20s.
Sarepta Therapeutics Inc. is best known for the storm of controversy around its Duchenne muscular dystrophy therapy Exondys 51, which was approved in 2016, but CEO Douglas Ingram is betting that soon, ...